ART + placebo

ART + placebo refers to the control arm used in clinical research, specifically in trials evaluating treatments for HIV-1 infection. This regimen consists of standard-of-care combination antiretroviral therapy (ART or cART) paired with an inactive placebo. ART is a multi-drug regimen typically comprising small molecule inhibitors that target various stages of the HIV-1 life cycle, including reverse transcriptase, protease, and integrase, to maintain viral suppression. In the context of the "shock and kill" strategy for HIV cure research, such as the Phase 2/3 trial (NCT02902185) sponsored by Tang-Du Hospital, this arm serves as a comparator to evaluate the efficacy of latency-reversing agents like the HDAC inhibitor chidamide (tucidinostat) in reactivating and reducing the latent HIV-1 reservoir in patients with suppressed viral loads.

Other names

antiretroviral therapy + placebocART + placeboHAART + placebo